•
Jun 30, 2022

Prelude Therapeutics Q2 2022 Earnings Report

EPS
-$0.58
Previous year: -$0.58
+0.0%
Cash and Equivalents
$50.7M
Previous year: $343M
-85.2%
Free Cash Flow
-$19.2M
Previous year: -$20.3M
-5.3%
Total Assets
$259M
Previous year: $350M
-25.9%

Prelude Therapeutics

Prelude Therapeutics